The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Summary

The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis and to investigate safety of TAU-284.

Timeline

Start

2013-04

Primary completion

2013-12

Completion

2013-12

Outcome

Met primary endpoint

paper Bepotastine besilate was superior to placebo in terms of total nasal symptom scores, with improved overall nasal symptoms of PAR compared with baseline values. PMID 26364765 ↗

Publications

• Results Okubo K, Ichimura M, Koyama T, Susuta Y, Izaki H. Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis. Expert Opin Pharmacother. 2015;16(16):2395-408. doi: 10.1517/14656566.2015.1085511. Epub 2015 Sep 12.

Drugs

Indications